

UNDER THE AUSPICES OF



ROME MAY 8/9, 2022
INTERNATIONAL SUMMIT ON
LUNG CANCER

SCIENTIFIC COMMITTEE
FEDERICO CAPPUZZO - SILVIA NOVELLO - GIORGIO SCAGLIOTTI

SCIENTIFIC SECRETARIAT
LORENZA LANDI - GABRIELE MINUTI



THE COLOSSEUM

Called by the ancient Romans, "Anphitheatrum Flavium" (Flavian Amphitheatre), the Colosseum is the most famous and impressive monument of ancient Rome, as well as the largest amphitheater in the world.

The name is undoubtedly linked to the large size of the building but derives above all from the fact that nearby there was a colossal statue of Nero and bronze.

In 1990, the **Colosseum**, along with all the historical center of Rome, the Vatican extraterritorial zones in Italy and the Basilica of St. Paul Outside the Walls, was listed as a World Heritage Site by UNESCO, while in July 2007 was included among the New seven Wonders of the World.

AM 09.00 **Registration**
10.00 **Message of IFO Scientific Director**
Gennaro Ciliberto

PREVENTION AND EARLY DETECTION OF LUNG CANCER

Chairs: Lucio Crinò, Ugo Pastorino

- 10.15 **Tobacco cessation among patients with lung cancer**
April Plank
- 10.35 **Radon as risk factor in lung cancer**
Laura Mezquita
- 10.55 **Early detection of lung cancer**
Ugo Pastorino

LIQUID BIOPSY AND NEW BIOMARKERS

Chairs: Fred Hirsch, Nicola Normanno

- 11.15 **Liquid biopsy for screening and early detection**
Gabriella Sozzi
- 11.30 **Liquid biopsy for guiding therapy decision**
Umberto Malapelle
- 11.45 **Neoantigen landscape and Tumor Mutational Burden**
Patrick Alexander Ott

NEOADJUVANT THERAPY OF LUNG CANCER

Chairs: Domenico Galetta, Francesco Grossi

- PM 12.00 **CheckMate 816 trial**
Jonathan Spicer
- 12.10 **Neoadjuvant with single agent immunotherapy**
Jair Bar
- 12.20 **Studies with neoadjuvant target therapy**
Masahiro Tsuboi
- 12.30 **Minimal Residual Disease assessment with Liquid Biopsy**
Christian Rolfo
- 12.40 **Pathological assessment following neoadjuvant therapy**
Sanja Dacic
- 01.00 Lunch

ADJUVANT THERAPY

Chairs: Anne-Marie Dingemans, Giorgio Scagliotti, Francesco Facciolo

- PM 02.00 **First-generation EGFR-TKIs in EGFR mutant NSCLC**
Yi Long Wu
- 02.10 **Osimertinib in surgically resected EGFR mutant NSCLC**
Christian Grohe
- 02.20 **Emerging target therapies in surgically resected NSCLC**
Francesco Grossi
- 02.30 **Atezolizumab in resected NSCLC**
Enriqueta Felip Font
- 02.40 **Other checkpoint inhibitors for resected NSCLC**
Simon Ekman
- 02.50 **Canakinumab in early stage NSCLC**
Giulia Pasello

INTEGRATED THERAPIES FOR STAGE III NSCLC

Chairs: Andrea Filippi, Piergiorgio Solli

- PM 03.00 **Radiotherapy for N2 resected NSCLC**
Alessio Morganti
- 03.10 **5 years OS in PACIFIC trial**
Andrea Filippi
- 03.20 **PACIFIC real world data**
Nicolas Girard
- 03.30 **Coast trial**
Fabrice Barlesi
- 03.40 **Pembrolizumab in unresectable NSCLC**
Rafal Dziadziuszko

PM 03.50 **Atezolizumab and tiragolumab in stage III NSCLC**

Alessandra Fontecedro Curioni

04.00 **Options at PACIFIC progression**

Federico Cappuzzo

Lecture

04.15 **The voice of lung cancer patients**

Anne Marie Baird

04.45 **Closing remarks**



ST. PETER'S BASILICA

The Papal Basilica of Saint Peter in the Vatican or simply Saint Peter's Basilica is a church built in the Renaissance style located in Vatican City, the papal enclave that is within the city of Rome.

It was initially planned by Pope Nicholas V and then Pope Julius II to replace the aging Old St. Peter's Basilica, which was built in the 4th century by Roman emperor Constantine the Great. Construction of the present basilica began on 18 April 1506 and was completed on 18 November 1626.

Designed principally by Donato Bramante, Michelangelo, Carlo Maderno and Gian Lorenzo Bernini, St. Peter's is the most renowned work of Renaissance architecture and the largest church in the world by interior measure.

DAY 2
MAY 9th, 2022

IMMUNOTHERAPY FOR NSCLC

Chairs: Solange Peters, Lorenza Landi

- AM 09.00 **Pembrolizumab or atezolizumab or cemiplimab in PD-L1 >50%**
Ed Garon
- 09.10 **KEYNOTE 189 and IMPOWER 150**
Howard Jack West
- 09.20 **Checkmate 9-LA**
Carlo Genova
- 09.30 **Tislelizumab for first-line NSCLC**
Marcello Tiseo
- 09.40 **EMPOWER Lung 3**
Raffaele Califano
- 09.50 **Chemofree options: Checkmate 227**
Solange Peters

TRINITÀ DEI MONTI

The Chiesa di Trinità dei Monti is perhaps better known for its location than for the works inside it. This little jewel has evolved with the centuries to become one of the most famous post cards of the Eternal City.

It stands atop the Spanish Steps, overlooking the Piazza di Spagna forming a backdrop that cannot be ignored. And yet, until the early 1500s, the church site was an enormous vineyard donated by King Charles VIII of France to an order of monks.

From the 16th century on, the entire area around the Trinità dei Monti had long been under French influence; in the 19th century, this influence expanded somewhat to include the Villa Medici and the French Academy. The French provided the funds for the celebrated Spanish Steps, which were built some time around 1725 by Francesco De Sanctis. Their purpose was to celebrate the peace between France and Spain by linking the Piazza di Spagna (so called because of a road leading to the Bourbon Spanish Embassy) to the French church.

EMERGING OPTIONS IN IMMUNE-PRETREATED NSCLC

Chairs: Federico Cappuzzo, Cesare Gridelli

- 10.00 **Chemofree options: POSEIDON**
Fred Hirsch
- 10.10 **KEYNOTE 598**
Keunchil Park
- 10.20 **Immunotherapy single agent versus combo: ETOP experience**
Rolf Stahel
- 10.30 **Tiragolumab and atezolizumab in first-line NSCLC**
Delvys Rodriguez- Abreu
- 10.40 **Bevacizumab and atezolizumab**
Alessandro Morabito

- AM 11.00 **Mechanisms of resistance to immunotherapy**
Paola Nisticò
- 11.10 **Novel strategies for overcoming resistance to checkpoint inhibitors**
Mark M. Awad
- 11.20 **Sitravatinib for immune-pretreated NSCLC**
Ross Soo
- 11.30 **TEDOPI**
Federico Cappuzzo
- 11.40 **Anti-TROP2**
Alexander Spira

BETWEEN IMMUNOTHERAPY AND TARGET THERAPY-ROLE OF KRAS

Chairs: Tony Mok, Ruggero De Maria

- PM 12.10 **KRAS and co-mutations. Impact of STK11 or KEAP1**
Ferdinandos Skoulidis
- 12.20 **Sotorasib**
Silvia Novello
- 12.30 **Adagrasib**
Stephen Liu
- 12.40 **Emerging agents in KRAS mutated**
Paolo Bironzo
- 01.00 Lunch

TARGET THERAPIES FOR NSCLC

Chairs: Emilio Bria, Rocco Trisolini

- PM 02.00 **FLAURA trial**
Pasi A. Jänne
- 02.10 **Osimertinib in combination with bevacizumab**
Pilar Garrido
- 02.20 **RET inhibitors in NSCLC**
Alex Drilon
- 02.30 **Drugging exon 20 mutations**
Rosario Garcia Campelo
- 02.40 **Trastuzumab deruxtecan in HER2 deregulated NSCLC**
Egbert Smit
- 02.50 **Dabrafenib and trametinib for BRAF mutant patients**
David Planchard
- 03.00 **Options for MET exon 14 mutated patients**
Oliver Gautschi
- 03.10 **Best first-line agent for ALK+ NSCLC: Who is the winner**
Tony Mok
- 03.20 **Options for ROS1+ NSCLC: crizotinib or entrectinib**
Lorenza Landi
- 03.30 **Options for NTRK rearranged tumors**
Alex Drilon
- 03.40 **NRG1: a new target in NSCLC**
Gabriele Minuti

SMALL CELL LUNG CANCER, MESOTHELIOMA AND THYMOMA

Chairs: Andrea Ardizzoni, Sara Pilotto

- PM 04.00 **Atezolizumab as first-line therapy in SCLC**
Andrea Ardizzoni
- 04.10 **Durvalumab as first-line therapy in SCLC**
Luis Paz-Ares Rodríguez
- 04.20 **Second-line options in SCLC**
Stephen Liu
- 04.30 **Nivolumab-ipilimumab in mesothelioma**
Francesco Grossi
- 04.40 **Second-line therapy in mesothelioma**
Dean Fennell
- 04.50 **Options for Thymomas**
Nicolas Girard
- 05.00 **Closing remarks**

ROME'S HISTORY SPANS 28 CENTURIES.

While Roman mythology dates the founding of Rome at around 753 BC, the site has been inhabited for much longer, making it a major human settlement for almost three millennia and one of the oldest continuously occupied cities in Europe. The city's early population originated from a mix of Latins, Etruscans, and Sabines.

Eventually, the city successively became the capital of the Roman Kingdom, the Roman Republic and the Roman Empire, and is regarded by many as the first-ever Imperial city and metropolis. It was first called The Eternal City by the Roman poet Tibullus in the 1st century BC, and the expression was also taken up by Ovid, Virgil, and Livy.

Rome is also called "Caput Mundi" (Capital of the World). After the fall of the Empire in the west, which marked the beginning of the Middle Ages, Rome slowly fell under the political control of the Papacy, and in the 8th century, it became the capital of the Papal States, which lasted until 1870. Beginning with the Renaissance, almost all popes pursued a coherent architectural and urban programme over four hundred years, aimed at making the city the artistic and cultural centre of the world. In this way, Rome became first one of the major centres of the Renaissance and then the birthplace of both the Baroque style and Neoclassicism. Famous artists, painters, sculptors, and architects made Rome the centre of their activity, creating masterpieces throughout the city.

In 1871, Rome became the capital of the Kingdom of Italy, which, in 1946, became the Italian Republic.

FACULTY**Andrea Ardizzoni**

Bologna - I

Mark M. Awad

Boston - US

Anne Marie Baird

Dublin - IRL

Jair Bar

Tel Aviv - IL

Fabrice Barlesi

Paris- F

Paolo Bironzo

Turin - I

Raffaele Califano

Manchester - UK

Federico Cappuzzo

Rome - I

Gennaro Ciliberto

Rome - I

Lucio Crinò

Meldola - I

Sanja Dacic

Pittsburgh - US

Anne-Marie Dingemans

Rotterdam - NL

Alexander Drilon

New York - US

Rafal Dziadziuszko

Gdansk - PL

Simon Ekman

Stockholm - S

Francesco Facciolo

Rome - I

Enriqueta Felip Font

Barcelona - E

Dean Fennell

Leicester - UK

Andrea Riccardo Filippi

Pavia - I

Alessandra Fontecedro Curioni

Zurich - CH

Domenico Galetta

Bari - I

Rosaria Garcia Campelo

Coruña - E

Edward B. Garon

Santa Monica - US

Pilar Garrido Lopez

Madrid - E

Oliver Gautschi

Lucerna - CH

Carlo Genova

Milan - I

Nicolas Girard

Paris - F

Cesare Gridelli

Avellino - I

Christian Grohe

Berlin - D

Francesco Grossi

Varese - I

Fred Hirsch

New York - US

Pasi A. Jänne

Boston - US

Lorenza Landi

Rome - I

Stephen Liu

Georgetown - US

Umberto Malapelle

Naples - I

Laura Mezquita

Barcelona - E

Gabriele Minuti

Ravenna - I

Tony Mok

Hong Kong - RC

Alessandro Morabito

Naples - I

Alessio Morganti

Bologna - I

Paola Nisticò

Rome - I

Nicola Normanno

Naples - I

Silvia Novello

Turin - I

Patrick Alexander Ott

Boston - US

Keunchil Park

Seoul - ROK

Giulia Pasello

Padua - I

Ugo Pastorino

Milan - I

Luis Paz-Ares Rodríguez

Sevilla - E

Solange Peters

Lausanne - CH

Sara Pilotto

Verona - I

David Planchard

Villejuif - F

April Plank

New York- US

Delvys Rodriguez-Abreu

Gran Canaria - E

Christian Rolfo

New York - US

Giorgio Vittorio Scagliotti

Turin - I

Ferdinandos Skoulidis

Houston - US

Egber Smit

Leida - NL

Piergiorgio Solli

Bologna - I

Ross Soo

Singapore - MY

Gabriella Sozzi

Milan - I

Jonathan Spicer

Montreal Trudeau - CDN

Alexander Spira

Fairfax - US

Rolf Stahel

Zurich - CH

Marcello Tiseo

Parma - I

Rocco Trisolini

Rome - I

Masahiro Tsuboi

Tokyo - J

Howard Jack West

Duarte - US

Yi-Long Wu

Guangdong - RC

INFO

VENUE

Hotel Le Meridien Visconti Rome

Via Federico Cesi, 37 Rome

REGISTRATION

Italian Participants log in:

fad.mitcongressi.it

Others:

www.mitcongressi.it and through email address: segreteria@mitcongressi.it

12 ECM FOR ITALIAN PARTICIPANTS ONLY

Medical specialties:

Pharmacy

Biology

Biomedical Technician

Medical Radiology Technician

Medical Physic

Surgeon Allergy and Immunology

Genetics

Pulmonary Disease

Internal Medicine

Oncology

Radiation Oncology

General Surgery

Thoracic Surgery

Anatomic and Clinical Pathology

Pharmacology and Medical Toxicology

Medical Biochemical Genetics

Nuclear Medicine

Diagnostic Radiology

Hospital Clinical management

Palliative Medicine

Cardiocirculatory and Cardiovascular Perfusion Technitian

Nurse

COVID FREE PROTOCOL AND POLICY

Please visit: www.salute.gov.it

ORGANIZING SECRETARIAT



Mi&T srl Centro Direzionale Bolomnia
Via Guelfa, 5 - 40138 Bologna
info@mitcongressi.it - www.mitcongressi.it



UNRESTRICTED GRANT BY

PLATINUM



GOLD



SILVER



BRONZE

